January 9, 2020 / 10:39 PM / 8 days ago

REFILE-BRIEF-Blueprint Medicines Expects Decision From European Commission On PDGFRA D842V GIST Indication In Q3 2020

(Corrects to add source)

Jan 9 (Reuters) - Blueprint Medicines Corp:

* BLUEPRINT MEDICINES - CONTINUES TO PURSUE CONDITIONAL MARKETING AUTHORIZATION FOR AVAPRITINIB FOR PDGFRA D842V MUTANT GIST IN EU

* BLUEPRINT MEDICINES - ANTICIPATES DECISION FROM EUROPEAN COMMISSION ON PDGFRA D842V GIST INDICATION IN Q3 2020 Source text: [bit.ly/306obBp] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below